Dr. Carl Dieffenbach: Key Developments in HIV Research from IAS 2013

Content From: Miguel Gomez, Director, AIDS.gov, and Senior Communications Advisor, Office of HIV/AIDS and Infectious Disease Policy, U.S. Department of Health and Human ServicesPublished: July 08, 20132 min read


Last week, Dr. Carl Dieffenbach from NIH/NIAID shared brief reports from the 7th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS 2013) with the HIV.gov community via Skype. As Dr. Dieffenbach related, some key highlights of the conference included:

  • Long-term HIV treatment strategies to address HIV as a chronic management disease;
  • The value of the HIV treatment cascade (also known as the “care continuum”) as a tool for healthcare professionals, public health officials, and policy makers to identify issues and opportunities related to improving the delivery of services to people living with HIV;
  • The social determinants of health that affect the spread of HIV and future directions in HIV vaccine research; and
  • Significant advances in HIV treatment.

Held every two years, the conference is a unique opportunity for the world’s leading scientists, clinicians, public health experts, and community leaders to examine the latest developments in HIV-related research and explore how scientific advances can inform the global response to HIV/AIDS.

Dr. Dieffenbach’s daily dispatches from IAS 2013 are available on the HIV.gov YouTube channelExit Disclaimer.

While the IAS Conference has ended, a great deal of information about the scientific research released at the conference is available for those who would like to learn more. The conference’s Programme-at-a GlanceExit Disclaimer includes links to session videos, slide sets with audio, rapporteur reports, and other content.

We also encourage you to check out the conference’s excellent Daily BulletinExit Disclaimer, with summaries of each day’s conference highlights.

To learn more about the IAS Conference, please visit the conference websiteExit Disclaimer or follow the conference on FacebookExit Disclaimer and TwitterExit Disclaimer.